Next-generation sequencing reveals germline mutations in an infant with synchronous occurrence of nephro- and neuroblastoma

Pediatr Hematol Oncol. 2016 May;33(4):264-75. doi: 10.1080/08880018.2016.1184362.

Abstract

Although neuro- and nephroblastoma are common solid tumors in children, the simultaneous occurrence is very rare and is often associated with syndromes. Here, we present a unique case of synchronous occurrence of neuro- and nephroblastoma in an infant with no signs of congenital anomalies or a syndrome. We performed genetic testing for possible candidate genes as underlying mutation using the next-generation sequencing (NGS) approach to target 94 genes and 284 single-nucleotide polymorphisms (SNPs) involved in cancer. We uncovered a novel heterozygous germline missense mutation p.F58L (c.172T→C) in the anaplastic lymphoma kinase (ALK) gene and one novel heterozygous rearrangement Q418Hfs(*)11 (c.1254_1264delins TTACTTAGTACAAGAACTG) in the Fanconi anemia gene FANCD2 leading to a truncated protein. Besides, several SNPs associated with the occurrence of neuroblastoma and/or nephroblastoma or multiple primary tumors were identified. The next-generation sequencing approach might in the future be useful not only in understanding tumor etiology but also in recognizing new genetic markers and targets for future personalized therapy.

Keywords: ALK; FANCD2; nephroblastoma; neuroblastoma; next-generation sequencing; predisposing genetic alterations; wilms tumor.

Publication types

  • Case Reports

MeSH terms

  • Anaplastic Lymphoma Kinase
  • Fanconi Anemia Complementation Group D2 Protein / genetics
  • Germ-Line Mutation*
  • High-Throughput Nucleotide Sequencing*
  • Humans
  • Infant
  • Kidney Neoplasms / genetics*
  • Kidney Neoplasms / therapy
  • Male
  • Neoplasms, Multiple Primary / genetics*
  • Neoplasms, Multiple Primary / therapy
  • Neuroblastoma / genetics*
  • Neuroblastoma / therapy
  • Polymorphism, Single Nucleotide
  • Receptor Protein-Tyrosine Kinases / genetics
  • Wilms Tumor / genetics*
  • Wilms Tumor / therapy

Substances

  • FANCD2 protein, human
  • Fanconi Anemia Complementation Group D2 Protein
  • ALK protein, human
  • Anaplastic Lymphoma Kinase
  • Receptor Protein-Tyrosine Kinases